UBS Group’s NeuroOne Medical Technologies NMTC Stock Holding History

UBS Group’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.97K	Buy	2,623 +2,605	+14,472%	+$10.6K	﹤0.01%	8719
2026 Q1	$84	Sell	18 -303	-94%	-$1.46K	﹤0.01%	10141
2025 Q4	$1.46K	Buy	321 +27	+9%	+$123	﹤0.01%	9575
2025 Q3	$1.57K	Buy	294 +276	+1,533%	+$1.35K	﹤0.01%	9316
2025 Q2	$73	Hold	18	–	–	﹤0.01%	10029
2025 Q1	$92	Hold	18	–	–	﹤0.01%	9956
2024 Q4	$89	Hold	18	–	–	﹤0.01%	9663
2024 Q3	$107	Sell	18 -9,533	-100%	-$47.7K	﹤0.01%	9153
2024 Q2	$45.8K	Buy	9,551 +9,533	+52,961%	+$59.9K	﹤0.01%	6756
2024 Q1	$130	Sell	18 -296	-94%	-$2.24K	﹤0.01%	8797
2023 Q4	$2.98K	Buy	314 +296	+1,644%	+$2.18K	﹤0.01%	8026
2023 Q3	$96	Hold	18	–	–	﹤0.01%	8898
2023 Q2	$130	Hold	18	–	–	﹤0.01%	8466
2023 Q1	$174	Sell	18 -182	-91%	-$1.69K	﹤0.01%	9158
2022 Q4	$1.44K	Buy	+200	New	+$1.79K	﹤0.01%	9869
2022 Q3	–	Sell	-147	Closed	-$1K	–	10723
2022 Q2	$1K	Buy	+147	New	+$818	﹤0.01%	9918

Other funds holding NMTC

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

UBS Group's NMTC Position: Q2 2026 in Review

UBS Group increased its NeuroOne Medical Technologies (NMTC) stake by 14,472% in Q2 2026, buying an estimated $10.6K and bringing the position to 2,623 shares worth $7.97K. The position accounts for ﹤0.01% of the portfolio, ranked #8719.

UBS Group first reported a position in NMTC in Q2 2022 and has held it in 16 quarters since. The position peaked at $45.8K in Q2 2024. 27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

UBS Group held 2,623 shares of NeuroOne Medical Technologies worth $7.97K as of Q2 2026.
UBS Group bought 2,605 NeuroOne Medical Technologies shares in Q2 2026, an estimated $10.6K.
NeuroOne Medical Technologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8719 holding.
UBS Group first reported a position in NeuroOne Medical Technologies in Q2 2022 and has held it in 16 quarters since.
UBS Group's NeuroOne Medical Technologies position peaked at $45.8K in Q2 2024.
27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.